EARLY-PRO-TECT
2020
Early Treatment of Children with Alport Syndrome
In 80 children with Alport syndrome, early ramipril delayed progression of albuminuria compared with placebo.
Result
Efficacy: Co-primary: safety (adverse drug reactions) and efficacy (time to disease progression)randomized arm HR 0.51 (95% CI 0.12-2.20)
Below 1 favours ramipril, above 1 favours placebo.
Also reported: Ramipril reduced disease-progression risk by ~half but not significantly ( ; Bayesian synthesis with open-arm data HR 0.52, 95% CI 0.19–1.39); safe (AE rate-ratio 1.00, 95% CI 0.66–1.53).
- Subtopic
- Alport syndrome
- Design
- Phase 3 RCT in paediatric patients
- Enrolled
- 66 patients
- Relevance
- Supporting: context rather than must-know.
- Source
- Gross O, et al. Kidney Int. 2020;97(6):1275-1286.doi 10.1016/j.kint.2019.12.015
Discussion & critique
Rare-disease trials are necessarily small; supports early RAS blockade in Alport syndrome. Bardoxolone (CARDINAL) later failed to gain approval.